39
Participants
Start Date
August 27, 2019
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2024
Prevenar13 (PCV13) and Pneumovax (PPS23)
One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
Placebo / Pneumovax (PPS23)
One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
Blood sample
an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
CIC 1417 Cochin-Pasteur - GH Broca-Cochin-Hôtel-Dieu, Paris
Collaborators (1)
EUCLID Clinical Trial Platform
OTHER
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
OTHER
CIC 1417 Cochin-Pasteur
OTHER
I-REIVAC Innovative Clinical Research Network In Vaccinology
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER